ArticleDigestive diseases and sciences2026
Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PAAD) remains one of the most lethal malignancies, with a 5-year survival rate below 10%. TCDD-inducible poly (ADP-ribose) polymerase (TIPARP) is aberrantly expressed in various tumors, but its mechanistic role and clinical significance in pancreatic cancer remain unclear.
methodsWe analyzed TIPARP expression patterns and prognostic relevance by integrating data from the TCGA-PAAD (n = 178) and GTEx (n = 171) databases. Single-cell RNA sequencing, immune infiltration profiling, and Mendelian randomization analyses were conducted to assess cell-type specificity and causal relationships. The biological functions of TIPARP were validated through in vitro assays, and downstream mechanisms were explored via pathway enrichment analysis.
resultsTIPARP was significantly upregulated in pancreatic cancer tissues and correlated with worse overall survival (P = 5.9e - 3) and progression-free survival (P = 0.01), serving as an independent prognostic risk factor. A TIPARP-based nomogram exhibited strong predictive performance (C-index = 0.666; 5-year AUC = 0.885). Single-cell transcriptomics identified fibroblasts as the primary TIPARP-expressing cell type. Immune profiling revealed that high TIPARP expression was associated with altered immune cell infiltration and positively correlated with immune checkpoint molecules such as PD-L1 and TIM-3. Mendelian randomization confirmed a causal association between genetically predicted TIPARP expression and increased PAAD risk (OR = 1.511, P = 0.008). Functional assays showed that TIPARP promotes cell proliferation, migration, and invasion, while pathway analysis implicated the PI3K-Akt and ECM-receptor interaction signaling cascades.
conclusionTIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.